Biotech News

Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Immutep Limited (IMMP)Immutep LimitedConference / presentation

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that data from two clinical trials of its first-in-class MHC Class II agonist, eftilagimod alfa (“efti”), will be presented in poster presentations at two international congresses in November and December 2026.

Related news

Immutep Limited

Immutep is a biotechnology company focused on immunotherapy and checkpoint modulation, with programs in cancer and immune disease. Its story is built around developing differentiated immune therapies that can complement existing oncology treatments.

Recent company news

Stock data

Close
3.42 USD
Market cap
61.31M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States